Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST)

被引：0

作者：

Blay, Jean-Yves

Molimard, Mathieu

Cropet, Claire

Domont, Julien

Toulmonde, Maud

Bompas, Emmanuelle

Cassier, Philippe Alexandre

Ray-Coquard, Isabelle Laure

Rios, Maria

Adenis, Antoine

Italiano, Antoine

Le Cesne, Axel

Bouche, Olivier

Mir, Olivier

Duffaud, Florence

Bertucci, Francois

Isambert, Nicolas

Belleville, Aurelie

Gautier, Julien

Perol, David

机构：

[1] Ctr Leon Berard, Dept Med, F-69373 Lyon, France

[2] Grp Hosp Pellegrin, Bordeaux, France

[3] Ctr Leon Berard, Unite Biostat & Evaluat Therapeut, Direct Rech & Innovat, F-69373 Lyon, France

[4] Inst Gustave Roussy, Villejuif, France

[5] Inst Bergonie, Dept Med Oncol, Bordeaux, France

[6] Ctr Rene Gauducheau, Dept Med Oncol, St Herblain, France

[7] Ctr Leon Berard, F-69373 Lyon, France

[8] Ctr A Vautrin, Nancy, France

[9] Ctr Oscar Lambret, Dept Med Oncol, F-59020 Lille, France

[10] CLCC Inst Bergonie, Bordeaux, France

[11] Ctr Hosp Univ Robert Debre, Reims, France

[12] La Timone Univ Hosp, Marseilles, France

[13] Inst J Paoli I Calmettes, F-13009 Marseille, France

[14] Ctr Georges Francois Leclerc, Dijon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10506

引用

下载

页数：1

共 39 条

[1] Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Mir, Olivier
Cropet, Claire
Toulmonde, Maud
Le Cesne, Axel
Molimard, Mathieu
Bompas, Emmanuelle
Cassier, Philippe
Ray-Coquard, Isabelle
Rios, Maria
Adenis, Antoine
Italiano, Antoine
Bouche, Olivier
Chauzit, Emmanuelle
Duffaud, Florence
Bertucci, Francois
Isambert, Nicolas
Gautier, Julien
Blay, Jean-Yves
Perol, David
LANCET ONCOLOGY, 2016, 17 (05): : 632 - 641
[2] A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)
Park, S. H.
Lim, D. H.
Park, K.
Lee, S.
Oh, S. Y.
Kwon, H.
Kang, J. H.
Hwang, I. G.
Lee, J.
Park, J. O.
Park, Y. S.
Lim, H. Y.
Kang, W. K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] Vinorelbine plus best supportive care (BSC) vs BSC in the treatment of advanced non small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
Clerici, M
Frontini, L
Ianniello, GP
Maiorino, L
Piantedosi, FV
Cigolari, S
Manzione, L
Failla, G
Zuccarino, L
Pedicini, T
Vinante, O
Castiglione, F
Bearz, A
Tonato, M
Rossi, A
Monfardini, S
Gallo, C
Perrone, F
Gridelli, C
ANNALS OF ONCOLOGY, 1998, 9 : 62 - 62
[4] A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
Jassem, Jacek
Ramlau, Rodryg
Santoro, Armando
Schuette, Wolfgang
Chemaissani, Assad
Hong, Shengyan
Blatter, Johannes
Adachi, Susumu
Hanauske, Axel-R
Manegold, Christian
ANNALS OF ONCOLOGY, 2006, 17 : 214 - 214
[5] Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Valencia, Ricardo Villalobos
Srinivasan, Krishnan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (Pts). Results of a phase III randomized trial
Gridelli, C
Ianniello, GP
Maiorino, L
Brancaccio, L
Cigolari, S
Bilancia, D
Aiello, R
Zuccarino, L
Pedicini, T
Zonato, S
Pappagallo, GL
Monfardini, S
Rossi, A
Gallo, C
Perrone, F
BRITISH JOURNAL OF CANCER, 1998, 78 : 3 - 3
[7] Vinorelbine(VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
Gridelli, C
Ianniello, GP
Maiorino, L
Piantedosi, V
Cigolari, S
Manzione, L
Failla, G
Zuccarino, L
Pedicini, T
Vinante, O
Castiglione, F
Clerici, M
Bearz, A
Darwish, S
Rossi, A
Monfardini, S
Gallo, C
Perrone, F
Frontini, L
ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
[8] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
Chen, Eric Xueyu
Jonker, Derek J.
Kennecke, Hagen F.
Koski, Sheryl L.
Wei, Alice Chia-chi
Magoski, Nadine M.
Tu, Dongsheng
O'Callaghan, Christopheri J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Capecitabine 1best supportive care (BSC) or erlotinib plus BSC as overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT)
Kataria, B.
Sharma, A.
Mishra, S.
Bhatnagar, S.
Thulkar, S.
Yadav, M.
Sahoo, R. K.
Pramanik, R.
Prasad, C. P.
Sreenivas, V.
ANNALS OF ONCOLOGY, 2019, 30 : 279 - 279
[10] Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
Kang, Y-K.
Kang, W. K.
Di Bartolomeo, M.
Chau, I.
Yoon, H. H.
Cascinu, S.
Ryu, M-H.
Kim, J. G.
Lee, K-W.
Oh, S. C.
Takashima, A.
Kryzhanivska, A.
Chao, Y.
Vladimirov, V.
Evesque, L.
Schenker, M.
McGinn, A.
Sankar, N.
Wyrwicz, L.
Boku, N.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 →